Recro Pharma (REPH) Tops Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results
March 25, 2015 8:01 AM EDTOn Track to Report Top-Line Phase II Data from Dex-IN Post Op Day 1 Trial in Mid 2015 Strengthened Company with Expected Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes
MALVERN, Pa., March 25, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post operative pain, today reported financial results for the fourth quarter and full year ended December 31, 2014.
"In late 2014 and early 2015 we made significant advancements on both... More
